Ariad Pharmaceuticals Inc fka ARIA

[LUMA14]

Scientists find 'chink in armour' of aggressive childhood cancer

link to article

...
The drugs pazopanib, dasatinib and sunitinib were all successful at inhibiting the protein from the PDGFRA gene – but if high levels of protein from the other gene, called FGFR1, remained, the cancer returned and would not respond to treatment even at higher doses. This may explain why, when doctors have tried chemotherapy with their young patients, even where it has worked at first, resistance has quickly set in.

An existing drug called ponatinib, currently in use as treatment for leukaemia, can target both proteins at once. But there are questions over the safety of the drug in children, so there will be a need to screen other drugs to find one with fewer side effects that works.
...

Meanwhile try Ponatinib?